Cancer-testis Antigen OY-TES-1 Expression and Immunogenicity in Hepatocellular Carcinoma
- PDF / 1,518,080 Bytes
- 10 Pages / 595.276 x 841.89 pts (A4) Page_size
- 83 Downloads / 146 Views
40(4):719-728,2020
719
Cancer-testis Antigen OY-TES-1 Expression and Immunogenicity in Hepatocellular Carcinoma* Bin LUO1†, Xiang YUN2†, Jing LI3†, Rong FAN4, Wen-wen GUO5, Chang LIU2, Yong-da LIN1, Ying-ying GE1, Xia ZENG1, Shui-qing BI1, Wei-xia NONG1#, Qing-mei ZHANG1#, Xiao-xun XIE1, 6, 7# 1 School of Basic Medical Sciences, Guangxi Medical University, Nanning 530021, China 2 Department of Surgery, the First Affiliated Hospital, Guangxi Medical University, Nanning 530021, China 3 Clinical Laboratory, Chinese Medicine Hospital, Quanzhou 362000, China 4 School of Basic Medical Sciences, Guangxi University of Chinese Medicine, Nanning 530021, China 5 Department of Pathology, the People’s Hospital of Guangxi Zhuang Autonomous Region, Nanning 530021, China 6 Guangxi Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor, Guangxi Medical University, Nanning 530021, China 7 Key Laboratory Research on Preclinical Medicine, Guangxi Medical University, Nanning 530021, China Huazhong University of Science and Technology 2020
Summary: Cancer testis (CT) antigens have received particular attention in cancer immunotherapy. OY-TES-1 is a member of CT antigens. This study was to evaluate OY-TES-1 expression and immunogenicity in hepatocelluar carcinoma (HCC). OY-TES-1 mRNA expression was detected in 56 HCC tissues and 5 normal liver tissues by reverse transcriptase PCR (RT-PCR). Of the 56 cases of HCC tissues tested, 37 cases had tumor and matched adjacent non-cancer tissues and were subjected to both RT-PCR and quantitative real-time PCR. OY-TES-1 protein was subsequently observed on a panel of tissue microarrays. Sera from patients were tested for OY-TES-1 antibody by ELISA. To identify OY-TES-1 capable of inducing cellular immune response, OY-TES-1 protein was used to sensitize dentritic cells and the cytotoxicity effect was measured in vitro. The results showed that OY-TES-1 mRNA was highly expressed in 41 of the 56 (73.21%) HCC tissues, whereas none in 5 normal liver tissues. OY-TES-1 mRNA was frequently expressed not only in HCC tissues (72.97%, 27/37), but also in paired adjacent non-cancer tissues (64.86%, 24/37). But the mean expression level of OY-TES-1 mRNA in HCC tissues was significantly higher than that in adjacent non-cancer tissues (0.76854 vs. 0.09834, P=0.021). Immunohistochemistry showed that OY-TES-1 protein expression was detected in 6 of the 49 cases of HCC tissues, and absent in 9 cases of normal liver and 6 cases of cirrhosis tissues. Seropositivity was detected in 10 of the 45 HCC patients, but not detected in 17 cirrhosis patients and 76 healthy donors. The specific cytotoxic T cells elicited by OY-TES-1 could kill HLA-A 2+ HCC cell line which expressed OY-TES-1. The target lysis was mainly HLA Bin LUO, E-mail: [email protected]; Xiang YUN, class Ⅰ-dependent and could be blocked by antibodies E-mail:[email protected]; Jing LI, E-mail: lijing046352 against monomorphic HLA class Ⅰ but not HLA class @163.com † Ⅱ molecule. In summary, OY-TES-1 expression is upThe Auth
Data Loading...
